Overprescription of short-acting β₂ -agonists among patients with asthma in Saudi Arabia: Results from the SABINA III cohort study.

ABSTRACT: Despite near-universal health care and timely updates to treatment guidelines in Saudi Arabia, asthma control remains suboptimal, warranting deeper exploration of its management practices. This study describes asthma characteristics and prescription patterns of short-acting β₂ -agonists (SABAs) in the Saudi Arabia cohort of the SABA use IN Asthma (SABINA) III study. Patients with asthma (aged ≥12 years) from seven sites across Saudi Arabia participated in this cross-sectional study. Asthma severity was classified by study investigators, guided by the 2017 Global Initiative for Asthma (GINA) recommendations. Of 511 patients enrolled, 502 patients, treated by respiratory medicine specialists, were analyzed (mean [standard deviation] age, 47.5 [14.8] years; female, 68.5%). Most pat

SUBMITTER: Al-Jahdali H 

PROVIDER: S-EPMC9716708 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature